AI-powered contentSome parts of this article are powered by AI.
Share this article
Gotrade News - Clorox (CLX) reported net sales up 33% to $1.91 billion for the first quarter of fiscal year 2027, which ended September 30, 2026, according to Clorox's official release on Monday, November 2, 2026. Diluted EPS increased 114% to $1.39 from $0.65 a year earlier.
Regular-session close on November 2, 2026, New York time. Prices and changes: Yahoo Finance, cross-checked against the closing price on Nasdaq.com. Market cap: that close times the shares outstanding on the latest 10-Q or 10-K cover (SEC EDGAR).
Clorox Earnings Details
All comparisons in the release are with the first quarter of fiscal year 2026. The GOJO acquisition accounted for about 15 points of the 33% net sales growth, and organic sales increased 18%, which the company said reflects lapping the ERP transition-related inventory drawdown in the year-ago quarter. Gross margin decreased 130 basis points to 40.4% from 41.7%, primarily driven by higher commodity costs and higher manufacturing and logistics costs, according to the company.
Adjusted EPS increased 82% to $1.55 from $0.85, which Clorox attributed primarily to higher net sales, cost savings and a lower tax rate. Year-to-date net cash provided by operations was $143 million, compared with $93 million a year earlier. Organic sales and adjusted EPS are non-GAAP measures. By segment, net sales increased 62% in Health and Wellness, where GOJO contributed approximately 39 points, 17% in Household, 16% in Lifestyle and 11% in International.
"We made good progress in the first quarter, delivering better-than-expected results through strong execution and timing benefits," Chair and CEO Linda Rendle said in the release.
Why It Matters for CLX
The release links the quarter's growth to the year-ago comparison. Retailers drew down inventory during the company's ERP transition in fiscal year 2026, and Clorox said lapping that drawdown gave about 18 points of benefit to first-quarter organic sales. The company said its adjusted EPS growth rate reflects the same lap, which was about 90 cents.
For fiscal year 2027, Clorox is maintaining its sales and adjusted EPS outlook ranges but now expects adjusted EPS results closer to the low end of the range, based on its latest assumptions on input costs and acquisition synergies, according to the release filed with the SEC. Net sales are still expected to be up 13% to 14%, adjusted EPS between $5.70 and $6.00 and diluted EPS between $5.41 and $5.71. Gross margin is now expected to be about 41.5%, which the company said reflects higher-than-normal inflationary headwinds. "The cost environment has become more challenging," Rendle said, adding that the company has "plans in place to mitigate these pressures."
This article is for education and information only and is not investment advice. Investment decisions are yours to make after your own research.
This article was written with the help of AI and checked by the Gotrade team before publishing.
Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA). This content is for educational purposes only and does not constitute financial advice. Always do your own research (DYOR) before investing.
M. Alfathan Rahman is a content writer with over 3 years of experience developing digital content strategies across various industries, including fintech. He has experience producing content for tax-related websites and financial education platforms. His focus areas include data research, and crafting financial articles that are informative, accurate, and accessible to investors of all experience levels.
